SCHEMBL7148635

SCHEMBL7148635

[CH2]CCc1nc(-c2ccc(OC)cc2)no1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 1/20 0.70
MAPT P10636 7/20 0.68
L3MBTL1 Q9Y468 6/20 0.68
NPC1 O15118 3/20 0.68
RAB9A P51151 3/20 0.68
LMNA P02545 4/20 0.67
ATM Q13315 1/20 0.67
TDP1 Q9NUW8 4/20 0.59
SMN1; SMN2 Q16637 3/20 0.59
KDM4E B2RXH2 3/20 0.59
TSHR P16473 3/20 0.59
HTT P42858 3/20 0.59
KMT2A Q03164 2/20 0.59
MEN1 O00255 1/20 0.59
ALOX15 P16050 1/20 0.59
MAPK1 P28482 1/20 0.59
HSD17B10 Q99714 1/20 0.58
CASP3 P42574 1/20 0.58
SENP8 Q96LD8 1/20 0.58
SENP7 Q9BQF6 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7952282 0.86 SIRT2 (0.72) SIRT2MAPTL3MBTL1NPC1RAB9A
SCHEMBL7296066 0.82 SIRT2 (0.75) SIRT2MAPTL3MBTL1NPC1RAB9A
SCHEMBL15133520 0.82 KMT2A (0.63) SIRT2MAPTL3MBTL1NPC1RAB9A
SCHEMBL8900040 0.81 LMNA (0.66) SIRT2MAPTL3MBTL1NPC1RAB9A
SCHEMBL14788168 0.81 SIRT2 (0.74) SIRT2MAPTL3MBTL1NPC1RAB9A
SCHEMBL17513948 0.81 SIRT2 (0.65) SIRT2MAPTL3MBTL1NPC1RAB9A
SCHEMBL1220782 0.81 SMN1; SMN2 (0.66) SIRT2MAPTL3MBTL1NPC1RAB9A
SCHEMBL3265992 0.81 SIRT2 (0.73) SIRT2MAPTL3MBTL1NPC1RAB9A
SCHEMBL101993 0.81 SIRT2 (0.65) SIRT2MAPTL3MBTL1NPC1RAB9A
SCHEMBL29376403 0.80 HTR1A (0.71) SIRT2MAPTL3MBTL1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0952157-B1 9A, 11B-Dehydro derivatives of 9-oxime-3-keto-6-0-methylerythromycin PFIZER PROD INC (US) 2003-06-18 EP claimed
US-6482801-B2 THERAPY FOR BACTERIAL OR PROTOZOA INFECTIONS PFIZER INC. 2002-11-19 US claimed
US-20010016574-A1 9a,11b-dehydro derivatives of 9-oxime-3-keto-6-O- methylerythromycin WU YONG-JIN (US) 2001-08-23 US claimed
US-6262030-B1 Erythromycin derivatives PFIZER INC. 2001-07-17 US claimed
US-6248719-B1 Tricyclic 3-keto derivatives of 6-O-methylerthromycin PFIZER INC 2001-06-19 US claimed
WO-1999062920-A1 TRICYCLIC 3-KETO DERIVATIVES OF 6-O-METHYLERYTHROMYCIN PFIZER PRODUCTS INC. (US) 1999-12-09 WO claimed
EP-0952157-A1 9A, 11B-Dehydro derivatives of 9-oxime-3-keto-6-0-methylerythromycin Pfizer Products Inc. (US) 1999-10-27 EP claimed
EP-0952157-B1 9A, 11B-Dehydro derivatives of 9-oxime-3-keto-6-0-methylerythromycin PFIZER PROD INC (US) 2003-06-18 EP disclosed
US-6482801-B2 THERAPY FOR BACTERIAL OR PROTOZOA INFECTIONS PFIZER INC. 2002-11-19 US disclosed
US-20010016574-A1 9a,11b-dehydro derivatives of 9-oxime-3-keto-6-O- methylerythromycin WU YONG-JIN (US) 2001-08-23 US disclosed
US-6262030-B1 Erythromycin derivatives PFIZER INC. 2001-07-17 US disclosed
US-6248719-B1 Tricyclic 3-keto derivatives of 6-O-methylerthromycin PFIZER INC 2001-06-19 US disclosed
WO-1999062920-A1 TRICYCLIC 3-KETO DERIVATIVES OF 6-O-METHYLERYTHROMYCIN PFIZER PRODUCTS INC. (US) 1999-12-09 WO disclosed
EP-0952157-A1 9A, 11B-Dehydro derivatives of 9-oxime-3-keto-6-0-methylerythromycin Pfizer Products Inc. (US) 1999-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010016574-A1 9a,11b-dehydro derivatives of 9-oxime-3-keto-6-O- methylerythromycin CYP7A1, HSD17B7, CYP51A1 SIRT2 2070/4885MAPT 4424/4885L3MBTL1 2095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.